Literature DB >> 33796797

Replacement of polyps with type 1 macular neovascularization in polypoidal choroidal vasculopathy imaged with swept source OCT angiography.

Mengxi Shen1, Qiyu Bo2, Minlu Song2, Xiaoshuang Jiang1,3, Zohar Yehoshua1, Giovanni Gregori1, Xiaodong Sun2,4,5,6,7, Fenghua Wang2,4,5,6,7, Philip J Rosenfeld1.   

Abstract

PURPOSE: To investigate the morphological changes of polyps in eyes with polypoidal choroidal vasculopathy (PCV) after treatment with vascular endothelial growth factor (VEGF) inhibitors using swept source optical coherence tomography angiography (SS-OCTA). OBSERVATIONS: Following anti-VEGF therapy, polyps were found to evolve into typical type 1 macular neovascularization (MNV) in five eyes. In all of these five eyes, a polypoidal lesion was detected adjacent to a serous or hemorrhagic retinal pigment epithelial detachment (PED). CONCLUSIONS AND IMPORTANCE: Polypoidal lesions in PCV can evolve into typical type 1 MNV. This morphological evolution suggests that these polyps are clusters of tangled vessels that can proliferate into a more typical neovascular pattern, and this evolution may be facilitated by being adjacent to a PED. Since this morphological appearance could be associated with a better prognosis, SS-OCTA might be helpful in identifying cases of transformed polyps that may be associated with a decreased risk for vision loss.
© 2021 The Authors.

Entities:  

Keywords:  Anti-vascular endothelial growth factor treatment; Polyp; Polypoidal choroidal vasculopathy; Swept source OCT angiography; Type 1 macular neovascularization

Year:  2021        PMID: 33796797      PMCID: PMC7995480          DOI: 10.1016/j.ajoc.2021.101057

Source DB:  PubMed          Journal:  Am J Ophthalmol Case Rep        ISSN: 2451-9936


  21 in total

1.  The origins of polypoidal choroidal vasculopathy.

Authors:  M Yuzawa; R Mori; A Kawamura
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

2.  Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.

Authors:  Hae Min Kang; Hyoung Jun Koh
Journal:  Am J Ophthalmol       Date:  2013-07-24       Impact factor: 5.258

3.  A Comparison Study of Polypoidal Choroidal Vasculopathy Imaged with Indocyanine Green Angiography and Swept Source OCT Angiography.

Authors:  Kiyoung Kim; William Feuer; Giovanni Gregori; Eung Suk Kim; Philip J Rosenfeld; Seung-Young Yu
Journal:  Am J Ophthalmol       Date:  2020-05-20       Impact factor: 5.258

4.  Comparison of swept source optical coherence tomography and spectral domain optical coherence tomography in polypoidal choroidal vasculopathy.

Authors:  Daniel S W Ting; Gemmy C M Cheung; Laurence S Lim; Ian Y S Yeo
Journal:  Clin Exp Ophthalmol       Date:  2015-08-06       Impact factor: 4.207

5.  Idiopathic polypoidal choroidal vasculopathy (IPCV).

Authors:  L A Yannuzzi; J Sorenson; R F Spaide; B Lipson
Journal:  Retina       Date:  1990       Impact factor: 4.256

6.  Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.

Authors:  Adrian Koh; Timothy Y Y Lai; Kanji Takahashi; Tien Y Wong; Lee-Jen Chen; Paisan Ruamviboonsuk; Colin S Tan; Chrystel Feller; Philippe Margaron; Tock H Lim; Won Ki Lee
Journal:  JAMA Ophthalmol       Date:  2017-11-01       Impact factor: 7.389

7.  Incidence Rate of Massive Submacular Hemorrhage and its Risk Factors in Polypoidal Choroidal Vasculopathy.

Authors:  Joon Hee Cho; Na-Kyung Ryoo; Kwan Hyuk Cho; Sang Jun Park; Kyu Hyung Park; Se Joon Woo
Journal:  Am J Ophthalmol       Date:  2016-06-16       Impact factor: 5.258

8.  Evaluating Polypoidal Choroidal Vasculopathy With Optical Coherence Tomography Angiography.

Authors:  Min Wang; Yao Zhou; Simon S Gao; Wei Liu; Yongheng Huang; David Huang; Yali Jia
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-07-01       Impact factor: 4.799

Review 9.  Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of 'expanded spectra' - a review.

Authors:  Kunal K Dansingani; Orly Gal-Or; Srinivas R Sadda; Lawrence A Yannuzzi; K Bailey Freund
Journal:  Clin Exp Ophthalmol       Date:  2017-12-26       Impact factor: 4.207

10.  Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.

Authors:  Tock H Lim; Timothy Y Y Lai; Kanji Takahashi; Tien Y Wong; Lee-Jen Chen; Paisan Ruamviboonsuk; Colin S Tan; Won Ki Lee; Chui Ming Gemmy Cheung; Nor Fariza Ngah; Ramune Patalauskaite; Philippe Margaron; Adrian Koh
Journal:  JAMA Ophthalmol       Date:  2020-09-01       Impact factor: 7.389

View more
  1 in total

1.  Choroidal Changes in Eyes With Polypoidal Choroidal Vasculopathy After Anti-VEGF Therapy Imaged With Swept-Source OCT Angiography.

Authors:  Mengxi Shen; Hao Zhou; Kiyoung Kim; Qiyu Bo; Jie Lu; Rita Laiginhas; Xiaoshuang Jiang; Quan Yan; Prashanth Iyer; Omer Trivizki; Yingying Shi; Luis de Sisternes; Mary K Durbin; William Feuer; Giovanni Gregori; Ruikang K Wang; Xiaodong Sun; Fenghua Wang; Seung-Young Yu; Philip J Rosenfeld
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-12-01       Impact factor: 4.799

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.